Highlight Product and Topics
*The products are still under development and not commercially available yet. Its future availability cannot be ensured. Siemens Healthineers neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S. the ELF Test is not for use in the diagnosis of NASH or for the staging of fibrosis. The ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.